Intellia Therapeutics (NTLA) BofA Securities 2025 Healthcare Conference summary

Strategic focus and operational updates

• Emphasis on late-stage gene editing programs with two assets in three phase III studies targeting ATTR and HAE indications.

• Company restructured early in the year to align financial planning with clinical priorities, resulting in strong operational momentum and execution ahead of estimates.

• Multiple catalysts expected over the next 12 to 18 months, including key data readouts and potential regulatory milestones.

• Cash balance exceeds $700 million, supporting full execution of phase III programs and U.S. commercial infrastructure build-out through at least the first half of 2027.

• Restructuring has focused resources on late-stage programs while maintaining a streamlined research effort.

ATTR program developments

• Two phase III studies underway: one for cardiomyopathy (CM) and one for polyneuropathy (PN), with CM enrollment expected to complete by end of 2026.

• ATTR program aims for deep, rapid, and durable TTR reduction, with phase I data showing consistent knockdown and a strong safety profile.

• No enrollment slowdown observed despite recent competitor approvals; momentum has increased following positive data disclosures.

• Phase III studies use co-primary endpoints, including TTR reduction and functional/clinical outcomes such as mortality, hospitalization, and quality-of-life metrics.

• Commercial strategy for ATTR will scale with market size, starting with smaller indications and expanding infrastructure for larger CM market.

HAE program progress

• Pivotal phase III HAE study enrollment accelerated, now expected to complete in Q3, less than nine months from first to last patient.

• HAE program targets a one-time gene-editing treatment aiming for complete elimination of attacks and no ongoing therapy.

• Phase I and II data show high attack rate reductions, with phase II design closely mirroring phase III; longer-term follow-up data expected later this year.

• Commercial preparation underway, with a focus on patient-driven market dynamics and payer engagement.

• Durability of response is a key differentiator, with early data supporting long-lasting effects and minimal need for redosing.